Chemotherapy can reduce a tumour enough for added treatments like radiation and surgery to be thought of. this is often said as neoadjuvant medical care by doctors. to reduce the severity of signs and symptoms. chemotherapy might assist to alleviate cancer symptoms by killing some cancer cells. Platinum-based compounds square measure key cancer chemotherapeutical medicines or medication prospects. as a result of a platinum atom is connected 2|to 2} ammonion molecules and two chloride ions, platinum-based medications are effective against cancer. The chemical is charged, however once it enters a neoplastic cell, the chloride ions are replaced by water molecules, and it becomes charged. ancient platinum medicines, like cisplatin, carboplatin, and oxaliplatin, square measure neutral platinum (II) complexes containing 2 amine ligands and 2 further ligands that may be aquated for hyperbolic desoxyribonucleic acid binding. Platinum-DNA adducts will hinder cellular processes and cause cell death.
Resistance to platinum medicines in tumours has become a tough drawback to resolve. personal cancer treatment that employs a range of the way to beat platinum-drug resistance in cancer patients is essential. ancient platinum drug structural alteration, platinum drug combination medical care with further agents, and increased platinum drug transport to tumour locations are a number of the key methods established to deal with difficulties with ancient platinum drug therapy.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Type, Distribution Channel, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Accord Healthcare, Novartis, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd, Debiopharm Group, Pfizer, Inc., Mylan N.V, Sanofi and Bristol-Myers Squibb Company |
The covid-19 Impact on Platinum Based Cancer Drug Market:
Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
Platinum Based Cancer Drug market Segment Overview
By Type, Cisplatin product segment accounted for the largest industry share in 2018 and can witness notable growth through 2026
By Applications, lung cancer application segment captured a considerable share of the market in 2018 and can seemingly drive a substantial product demand considerably. this could be attributed to the upper occurrence of pulmonary cancers among the worldwide population.
Market Analysis, Insights and Forecast – By Type
· Cisplatin
· Oxaliplatin
· Carboplatin
· Others
Market Analysis, Insights and Forecast – By Application
· Colorectal Cancer
· Ovarian Cancer
· Lung Cancer
· Others
Platinum Based Cancer Drug Market Regional Overview
Region-wise, in terms of regions ,Due to enhanced disease prevalence, increased awareness, enlarged per capita income, and increased health care infrastructure, the Asia Pacific market is anticipated to develop at the most important CAGR. North America dominated the world market in 2018 due to the high incidence of cancer within the region, developments in these medicine and recent Food and Drug Administration approvals. us is that the world’s largest drug market. This has led to the dominance of North America within the global platinum cancer drug market. The U.S. pharmaceutical trade is that the largest domestic market within the world. it's the world’s biggest continental pharmaceutical market in conjunction with North American nation and Mexico.
Platinum Based Cancer Drug Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Platinum Based Cancer Drug Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Platinum Based Cancer Drug are highlighted below.
· In 2021, Pfizer Inc. and therapeutics medical specialty therapeutics. had a definitive agreement consistent with that Pfizer acquired trillium, a clinical-stage immune-oncology business researching novel cancer medicines.
Platinum Based Cancer Drug Market, Key Players -
· Accord Healthcare,
· Novartis,
· Sun Pharmaceutical Industries Ltd.,
· Dr. Reddy’s Laboratories Ltd.,
· Jiangsu Hengrui Pharmaceutical Co., Ltd,
· Debiopharm Group,
· Pfizer, Inc.,
· Mylan N.V,
· Sanofi
· Bristol-Myers Squibb Company.
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Platinum Based Cancer Drug Market during the forecast period?
Q2. Which segment is projected to hold the largest share in the Platinum Based Cancer Drug Market?
Q3. What are the driving factors for the Platinum Based Cancer Drug Market?
Q4. Which Segments are covered in the Platinum Based Cancer Drug Market report?
Q5. Which are the prominent players offering Platinum Based Cancer Drug Market?
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Platinum Based Cancer Drug Market analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. •Cisplatin
- 5.2.2. •Oxaliplatin
- 5.2.3. •Carboplatin
- 5.2.4. •Others
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. •Colorectal Cancer
- 5.3.2. •Ovarian Cancer
- 5.3.3. •Lung Cancer
- 5.3.4. •Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East, and Africa
6. North America Platinum Based Cancer Drug Market Analysis(USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. •Cisplatin
- 6.2.2. •Oxaliplatin
- 6.2.3. •Carboplatin
- 6.2.4. •Others
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. •Colorectal Cancer
- 6.3.2. •Ovarian Cancer
- 6.3.3. •Lung Cancer
- 6.3.4. •Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. UK
- 6.4.2. Germany
- 6.4.3. France
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Rest of Europe
7. Asia Pacific Platinum Based Cancer Drug Market Analysis(USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. •Cisplatin
- 7.2.2. •Oxaliplatin
- 7.2.3. •Carboplatin
- 7.2.4. •Others
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. •Colorectal Cancer
- 7.3.2. •Ovarian Cancer
- 7.3.3. •Lung Cancer
- 7.3.4. •Others
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. China
- 7.4.2. India
- 7.4.3. Japan
- 7.4.4. Australia
- 7.4.5. South East Asia
- 7.4.6. Rest of Asia Pacific
8. Latin America, Middle East, and Africa Platinum Based Cancer Drug Market Analysis(USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. •Cisplatin
- 8.2.2. •Oxaliplatin
- 8.2.3. •Carboplatin
- 8.2.4. •Others
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. •Colorectal Cancer
- 8.3.2. •Ovarian Cancer
- 8.3.3. •Lung Cancer
- 8.3.4. •Others
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. Brazil
- 8.4.2. Saudi Arabia
- 8.4.3. UAE
- 8.4.4. Rest of LAMEA
9. Competitive Analysis
- 9.1. Company Market Share Analysis, 2018
- 9.2. Key Industry Developments
- 9.3. Company Profile
- 9.4. Pfizer Inc.,
- 9.4.1. Business Overview
- 9.4.2. Segment 1 & Service Offering
- 9.4.3. Overall Revenue
- 9.4.4. Geographic Presence
- 9.4.5. Recent Development
- 9.5. • Accord Healthcare,
- 9.6. • Novartis,
- 9.7. • Sun Pharmaceutical Industries Ltd.,
- 9.8. • Dr. Reddy’s Laboratories Ltd.,
- 9.9. • Jiangsu Hengrui Pharmaceutical Co., Ltd,
- 9.10. • Debiopharm Group,
- 9.11. • Mylan N.V,
- 9.12. • Sanofi
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
